Consequently, the committee decided to score this criterion
based on the information summarized and conclusions
drawn from MM (Table 3). Evidence of statin use for primary
and secondary preventions of adverse cardiovascular
events were considered both with respect to strength of the
recommendation and strength of the evidence. Strengths
of recommendations are categorized into Class I (recommended),
Class IIA (recommended in most cases), Class
IIB (recommended in some cases), and Class III (not recommended).
For strength of evidence, evidences based on data
derived from meta-analyses of randomized controlled trials
with homogeneity with regards to directions and degrees of
results between individual studies as well as evidences from
multiple randomized control trials involving large number of
patients are categorized into Category A. Evidences based on
data derived from meta-analyses of randomized controlled
trials with conflicting conclusions with regards to directions